New Drug to Treat Chemotherapy Overdose Receives FDA Approval

by Reshma Anand on  December 14, 2015 at 12:15 PM Drug News
RSS Email Print This Page Comment
The most common complication faced by cancer patients is chemotherapy overdose. The drug used in chemotherapy 5-fluorouracil (5-FU) or capecitabine is known for causing severe toxicity affecting the cardiac or central nervous system and allergic reactions in patients.
New Drug to Treat Chemotherapy Overdose Receives FDA Approval
New Drug to Treat Chemotherapy Overdose Receives FDA Approval
Advertisement

The Food and Drug Administration (FDA) has recently approved a drug called Vistogard (uridine triacetate) for treating patients suffering from chemotherapy overdose. The drug has showed positive results in its final clinical trial.

Advertisement
Uridine triacetate was tested on 135 adult and pediatric patients in two separate trials who had either overdosed on 5-FU or experienced life-threatening adverse events within 4 days of receiving 5-FU infusion therapy. Of those patients treated for overdose, 97% were alive after 30 days. Of those treated for toxicities, 89% were alive at 30 days.

The drug developed by Wellstat Therapeutics should be taken soon after overexposure - regardless of whether symptoms are present or early onset of severe toxicities, including severe mucositis, fever, diarrhea, or rash.

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Drug Toxicity Clinical Trials - Different Phases of the trial Chronic Lymphocytic Leukemia Hodgkins Lymphoma Non-Hodgkins Lymphoma Chemotherapy Chemotherapy Drugs Signature Drug Toxicity Peritoneal Cancer Rhabdomyosarcoma 
Advertisement

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive